18 research outputs found
Biomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model.
No full textBACKGROUND: The Japanese ‘BALAD' model offers the first objective, biomarker-based, tool for assessment of prognosis in hepatocellular carcinoma, but relies on dichotomisation of the constituent data, has not been externally validated, and cannot be applied to the individual patients. METHODS: In this Japanese/UK collaboration, we replicated the original BALAD model on a UK cohort and then built a new model, BALAD-2, on the original raw Japanese data using variables in their continuous form. Regression analyses using flexible parametric models with fractional polynomials enabled fitting of appropriate baseline hazard functions and functional form of covariates. The resulting models were validated in the respective cohorts to measure the predictive performance. RESULTS: The key prognostic features were confirmed to be Bilirubin and Albumin together with the serological cancer biomarkers, AFP-L3, AFP, and DCP. With appropriate recalibration, the model offered clinically relevant discrimination of prognosis in both the Japanese and UK data sets and accurately predicted patient-level survival. CONCLUSIONS: The original BALAD model has been validated in an international setting. The refined BALAD-2 model permits estimation of patient-level survival in UK and Japanese cohorts
Development of High-Performance and Flexible Protocol Handler for International Web Accesses
No full textThe \u27Galad Score\u27 for serological Detection of Hepatocellular Cercinoma: International Validation and Assesment of the Influence of Tumor size and Aetiology on Model Utility
No full textAssessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach - The albi grade
No full textAssessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach - The ALBI Grade
No full textRole of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients
No full textHighly Sensitive <i>Lens culinaris</i> Agglutinin-Reactive α-Fetoprotein: A New Tool for the Management of Hepatocellular Carcinoma
No full textBiomarker-based prognosis in hepatocellular carcinoma: validation and extension of the BALAD model
No full textBACKGROUND: The Japanese ‘BALAD' model offers the first objective, biomarker-based, tool for assessment of prognosis in hepatocellular carcinoma, but relies on dichotomisation of the constituent data, has not been externally validated, and cannot be applied to the individual patients. METHODS: In this Japanese/UK collaboration, we replicated the original BALAD model on a UK cohort and then built a new model, BALAD-2, on the original raw Japanese data using variables in their continuous form. Regression analyses using flexible parametric models with fractional polynomials enabled fitting of appropriate baseline hazard functions and functional form of covariates. The resulting models were validated in the respective cohorts to measure the predictive performance. RESULTS: The key prognostic features were confirmed to be Bilirubin and Albumin together with the serological cancer biomarkers, AFP-L3, AFP, and DCP. With appropriate recalibration, the model offered clinically relevant discrimination of prognosis in both the Japanese and UK data sets and accurately predicted patient-level survival. CONCLUSIONS: The original BALAD model has been validated in an international setting. The refined BALAD-2 model permits estimation of patient-level survival in UK and Japanese cohorts
Development of international mirroring system for real-time web of meteorological satellite data
No full text
